Sensyne Health names partners for US product launch
Initially, Sensyne will sell three software products managing a range of conditions, GDm-Health for gestational diabetes, EDGE for Chronic Obstructive Pulmonary Disease, and Support-HF, for heart failure.
“Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers,” commented Lord Paul Drayson, CEO of Sensyne Health.
GDm-Health, which will be the first to launch, is currently used by 15 NHS Trusts, helping over 6,100 patients in the UK manage and control gestational diabetes, which can lead to high blood pressure or premature birth.
All products were invented and developed in the UK’s NHS in collaboration with the University of Oxford, and then licensed to Sensyne Health.
The NHS and Sensyne will share financial returns under the agreements with Cognizant and Agorai via Sensyne’s unique partnership model.
"Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK's NHS, is realised in the US market,” Lord Drayson added.
Follow News & Updates from Sensyne Health:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.